ORPHA:582
Mucopolysaccharidosis type 4
Also known as: MPS4 · MPSIV · Morquio disease · Mucopolysaccharidosis type IV
Publications
2,604
Trials
2
Interventional, condition-specific
Researchers
1,134
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare lysosomal storage disease characterized by mild to severe spondylo-epiphyso-metaphyseal , manifesting with disproportionate short stature (short neck and trunk), joint laxity, pectus carinatum, genum valgum, abnormal gait, tracheal narrowing, spinal abnormalities (kyphosis and scoliosis), respiratory impairment and valvular heart disease.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018938
- UMLS:C0026707
- NCIT:C61263
Additional Mondo synonyms (8)
Morquio syndrome · Mucopolysaccharidosis IV · eccentro-osteochondrodysplasia · eccentrochondrodysplasia · eccentroosteochondrodysplasia · mucopolysaccharidosis IV · mucopolysaccharidosis type 4 · mucopolysaccharidosis type IV
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,604 matched papers (980 in last 10 years) Source
- Phenotype characterisedPresent
128 HPO annotations (e.g. Short neck; Pectus carinatum; Abnormal rib morphology) Source
- Animal modelPresent
2 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
128
Associated phenotypes · MONDO:0018938
- Short neck
- Pectus carinatum
- Abnormal rib morphology
- Abnormal metaphysis morphology
- Gait disturbance
Showing 5 of 128 — open Monarch for the full list.
Animal models (Monarch / Alliance)
2
Model associations linked to this Mondo ID
- Galnstm1Toma/Galnstm1Toma [background:] involves: 129X1/SvJ * C57BL/6·MGI:2686939·Mus musculus
- Galnstm2(GALNS)Toma/Galnstm2(GALNS)Toma [background:] involves: 129X1/SvJ * C57BL/6·MGI:3616632·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2,604
2,604 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2,604 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
980 in the last 10 years · low confidence
Phrase hits: 2,604 · MeSH hits: 0
Who's working on it?
1,134
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Tomatsu S10 papers · 2026
Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA.
Papers in Europe PMC - 02Magner M7 papers · 2026
Department of Pediatrics and Inherited Metabolic Disorders, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Papers in Europe PMC - 03
- 04Pachajoa H5 papers · 2025
Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad ICESI, Cali, Colombia.
Papers in Europe PMC - 05Bober MB4 papers · 2025
Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE, USA.
Papers in Europe PMC - 06Candelo E4 papers · 2025
Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad ICESI, Cali, Colombia.
Papers in Europe PMC - 07Diaz-Ordoñez L4 papers · 2025
Department of Basic Medical Sciences, Center for Research on Congenital Anomalies and Rare Diseases (CIACER), Universidad Icesi, Cali, Colombia.
Papers in Europe PMC - 08Lin HY4 papers · 2026
Department of Medicine, MacKay Medical College, New Taipei City 25245, Taiwan.
Papers in Europe PMC - 09Mackenzie WG4 papers · 2025
Department of Orthopedic Surgery, Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803-3607, USA; Jefferson Medical College, 1600 Rockland Road, Wilmington, DE 19803-3607, USA. Electronic address: wmackenz@nemours.org.
Papers in Europe PMC - 10Murgašová L4 papers · 2026
Department of Pediatrics and Inherited Metabolic Disorders, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 105 trials are registered for mucopolysaccharidosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
low confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: mucopolysaccharidosis
105
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05594992·ENROLLING BY INVITATION·An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
Not reviewed·Conditions: Mucopolysaccharidosis II·Matched via name phrase
- NCT05208281·RECRUITING·A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
Not reviewed·Conditions: Mucopolysaccharidosis Type II · Metabolic Diseases·Matched via name phrase
- NCT02716246·RECRUITING·Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Not reviewed·Conditions: MPS IIIA · Sanfilippo Syndrome · Sanfilippo A · Mucopolysaccharidosis III·Matched via name phrase
- NCT05371613·RECRUITING·A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Not reviewed·Conditions: Mucopolysaccharidosis II·Matched via name phrase
- NCT07136896·NOT YET RECRUITING·Nutritional Assessment in Patient of Mucopolysaccharide "
Not reviewed·Conditions: Mucopolysaccharidosis (MPS) · Malnutrition (Calorie) · Undernutrition·Matched via name phrase
- NCT06075537·ENROLLING BY INVITATION·An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Not reviewed·Conditions: Mucopolysaccharidosis II·Matched via name phrase
- NCT06519552·RECRUITING·A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
Not reviewed·Conditions: Mucopolysaccharidosis Type I·Matched via name phrase
- NCT06488924·RECRUITING·An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Not reviewed·Conditions: Mucopolysaccharidosis III-B·Matched via name phrase
- NCT04360265·ENROLLING BY INVITATION·Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
Not reviewed·Conditions: Mucopolysaccharidosis IIIA · MPS IIIA · Sanfilippo Syndrome · Sanfilippo A·Matched via name phrase
- NCT02254863·RECRUITING·UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Not reviewed·Conditions: Adrenoleukodystrophy · Batten Disease · Mucopolysaccharidosis II · Leukodystrophy, Globoid Cell·Matched via name phrase
- NCT06333041·RECRUITING·Study of Cannabidiol in Sanfilippo Syndrome
Not reviewed·Conditions: Sanfilippo Syndrome · Mucopolysaccharidosis III·Matched via name phrase
- NCT07579910·NOT YET RECRUITING·Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB
Not reviewed·Conditions: MPS IIIB·Matched via name phrase
- NCT05682144·RECRUITING·ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Not reviewed·Conditions: Mucopolysaccharidosis IH/S · Mucopolysaccharidosis IS·Matched via name phrase
- NCT07640984·NOT YET RECRUITING·A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Not reviewed·Conditions: Mucopolysaccharidosis IIIB·Matched via name phrase
Observational and natural-history studies
21 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05284006·RECRUITING·Non-invasive Functional Assessment and Pathogenesis of Morquio A
Not reviewed·Conditions: Mucopolysaccharidosis IV Type A · Morquio A Syndrome · MPS IVA·Matched via name phrase
- NCT03333200·RECRUITING·Longitudinal Study of Neurodegenerative Disorders
Not reviewed·Conditions: MLD · Krabbe Disease · ALD · MPS I·Matched via name phrase
- NCT06036693·RECRUITING·MPS (RaDiCo Cohort) (RaDiCo-MPS)
Not reviewed·Conditions: Mucopolysaccharidosis I · Mucopolysaccharidosis II · Mucopolysaccharidosis III · Mucopolysaccharidosis IV·Matched via name phrase
- NCT05619900·RECRUITING·Registry of Patients Diagnosed With Lysosomal Storage Diseases
Not reviewed·Conditions: Mucopolysaccharidosis I · Mucopolysaccharidosis II · Mucopolysaccharidosis IV A · Mucopolysaccharidosis VI·Matched via name phrase
- NCT05368038·ENROLLING BY INVITATION·ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Not reviewed·Conditions: Acid Sphingomyelinase Deficiency · Ceroid Lipofuscinosis, Neuronal, 2 · Cerebrotendinous Xanthomatosis · Fabry Disease·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- isrctn·ISRCTN13397128·No longer recruiting·A study of potential treatment-responsive biomarkers and clinical outcomes in Hunter syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16919215·No longer recruiting·Hydrotherapy in mucopolysaccharidosis II
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10369994·No longer recruiting·A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of MTL-CEBPA in children with mucopolysaccharidosis type IH
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12458940·No longer recruiting·Gene therapy in children with mucopolysaccharidosis II (MPSII) consented below the age of 22 months
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11652897·No longer recruiting·Study to determine the effectiveness and safety of DNL310 vs idursulfase in pediatric participants with neuronopathic or non-neuronopathic Hunter Syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19853672·No longer recruiting·Intra-cerebral gene therapy for Sanfilippo type B syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22324060·No longer recruiting·Efficacy and safety of enzyme replacement therapy for Mucopolysaccharidosis type I with 100 IU/Kg recombinant human a-L-iduronidase (Aldurazyme™)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82579275·No longer recruiting·Neck stabilization using the PERLA® Occipital fixation system
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Mucopolysaccharidosis type 4 — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mucopolysaccharidosis type 4" OR "MPSIV" OR "Morquio disease" OR "Mucopolysaccharidosis type IV" OR "Morquio syndrome" OR "Mucopolysaccharidosis IV" OR "eccentro-osteochondrodysplasia" OR "eccentrochondrodysplasia" OR "eccentroosteochondrodysplasia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mucopolysaccharidosis type 4" OR "MPSIV" OR "Morquio disease" OR "Mucopolysaccharidosis type IV" OR "Morquio syndrome" OR "Mucopolysaccharidosis IV" OR "eccentro-osteochondrodysplasia" OR "eccentrochondrodysplasia" OR "eccentroosteochondrodysplasia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 21 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"mucopolysaccharidosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MPS4
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (2604) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T14:26:38.016Z
